We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Recently, Antengene Corporation announced that the Phase I clinical trial application (IND) of its global first anti-CD24 monoclonal antibody, ATG-031, had been approved by FDA.